$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000139047814000063 Filed on November 05, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$3.200M	$1.620M	$2.166M
YoY Change	122.84%	-25.21%	0.0%
Cost Of Revenue	$480.0K	$247.0K	$258.0K
YoY Change	118.18%	-4.26%
Gross Profit	$2.720M	$1.373M	$1.454M
YoY Change	121.32%	-5.57%	0.0%
Gross Profit Margin	85.0%	84.75%	67.13%
Selling, General & Admin	$7.650M	$3.542M	$4.129M
YoY Change	22.79%	-14.22%	203.6%
% of Gross Profit	281.25%	257.98%	283.98%
Research & Development	$6.270M	$7.025M	$3.633M
YoY Change	-11.57%	93.37%	-12.86%
% of Gross Profit	230.51%	511.65%	249.86%
Depreciation & Amortization	$20.00K	-$120.0K	$130.0K
YoY Change	-83.33%	-192.31%	1200.0%
% of Gross Profit	0.74%	-8.74%	8.94%
Operating Expenses	$14.10M	$10.57M	$7.762M
YoY Change	4.83%	36.14%	40.41%
Operating Profit	-$11.38M	-$10.57M	-$6.893M
YoY Change	-6.88%	53.3%	24.69%
Interest Expense	$3.200M	$6.440M	-$1.110M
YoY Change	-109.23%	-680.18%	326.92%
% of Operating Profit
Other Income/Expense, Net	$230.0K	-$6.173M	-$8.128M
YoY Change	-160.53%	-24.05%	1008.87%
Pretax Income	-$7.960M	-$3.530M	-$8.128M
YoY Change	-83.2%	-56.57%	29.82%
Income Tax	$0.00	$0.00	$1.159M
% Of Pretax Income
Net Earnings	-$7.960M	-$6.173M	-$6.929M
YoY Change	44.31%	-10.91%	-61.56%
Net Earnings / Revenue	-248.75%	-381.05%	-319.9%
Basic Earnings Per Share		-$0.05	-$0.66
Diluted Earnings Per Share	-$1.921B	-$890.1M	-$3.191B
COMMON SHARES
Basic Shares Outstanding	121.5M shares	118.2M shares	84.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.70M	$24.60M	$54.23M
YoY Change	-50.4%	-54.64%	252.16%
Cash & Equivalents	$23.65M	$24.65M	$51.40M
Short-Term Investments			$2.837M
Other Short-Term Assets	$28.40M	$2.000M	$600.0K
YoY Change	1675.0%	233.33%	-33.33%
Inventory	$655.0K	$450.0K	$425.0K
Prepaid Expenses
Receivables	$1.839M	$1.435M	$1.543M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$52.10M	$28.52M	$56.79M
YoY Change	-24.26%	-49.77%	247.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$285.0K	$589.0K	$545.0K
YoY Change	-9.24%	8.07%	1658.06%
Goodwill	$5.897M	$5.898M	$5.898M
YoY Change	-0.02%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$7.800M	$100.0K
YoY Change	0.0%	7700.0%	0.0%
Total Long-Term Assets	$28.39M	$50.97M	$34.47M
YoY Change	47.92%	47.88%	82.69%
TOTAL ASSETS
Total Short-Term Assets	$52.10M	$28.52M	$56.79M
Total Long-Term Assets	$28.39M	$50.97M	$34.47M
Total Assets	$80.49M	$79.49M	$91.25M
YoY Change	-8.51%	-12.89%	159.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.886M	$3.360M	$1.890M
YoY Change	-1.1%	77.78%	-14.48%
Accrued Expenses	$8.885M	$15.29M	$8.889M
YoY Change	83.54%	72.03%	341.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.910M	$4.163M	$1.215M
YoY Change	81.95%	242.63%
Total Short-Term Liabilities	$27.23M	$31.59M	$36.51M
YoY Change	-56.41%	-13.5%	263.07%
LONG-TERM LIABILITIES
Long-Term Debt	$4.492M	$5.097M	$8.583M
YoY Change	-41.99%	-40.62%	8483.0%
Other Long-Term Liabilities	$6.700M	$6.900M	$6.500M
YoY Change	-1.47%	6.15%	10.17%
Total Long-Term Liabilities	$4.492M	$5.097M	$8.583M
YoY Change	-41.99%	-40.62%	43.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.23M	$31.59M	$36.51M
Total Long-Term Liabilities	$4.492M	$5.097M	$8.583M
Total Liabilities	$43.43M	$48.63M	$56.63M
YoY Change	-47.1%	-14.13%	169.34%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$256.4M	$242.2M	$167.1M
YoY Change	35.94%	44.94%	43.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.849M	$3.849M	$3.849M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	675.0K shares	675.0K shares	675.0K shares
Shareholders Equity	$37.06M	$30.86M	$34.62M
YoY Change
Total Liabilities & Shareholders Equity	$80.49M	$79.49M	$91.25M
YoY Change	-8.51%	-12.89%	159.3%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$7.960M	-$6.173M	-$6.929M
YoY Change	44.31%	-10.91%	-61.56%
Depreciation, Depletion And Amortization	$20.00K	-$120.0K	$130.0K
YoY Change	-83.33%	-192.31%	1200.0%
Cash From Operating Activities	-$10.73M	-$11.12M	-$7.990M
YoY Change	26.38%	39.17%	91.61%
INVESTING ACTIVITIES
Capital Expenditures	-$110.0K	-$20.00K	-$100.0K
YoY Change	-97.89%	-80.0%
Acquisitions			$10.00M
YoY Change
Other Investing Activities	$0.00	-$3.060M	$810.0K
YoY Change	-100.0%	-477.78%
Cash From Investing Activities	-$110.0K	-$3.080M	$720.0K
YoY Change	-96.07%	-527.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.850M	-330.0K	37.74M
YoY Change	28.09%	-100.87%	10383.33%
NET CHANGE
Cash From Operating Activities	-10.73M	-11.12M	-7.990M
Cash From Investing Activities	-110.0K	-3.080M	720.0K
Cash From Financing Activities	9.850M	-330.0K	37.74M
Net Change In Cash	-990.0K	-14.53M	30.47M
YoY Change	-72.5%	-147.69%	-899.74%
FREE CASH FLOW
Cash From Operating Activities	-$10.73M	-$11.12M	-$7.990M
Capital Expenditures	-$110.0K	-$20.00K	-$100.0K
Free Cash Flow	-$10.62M	-$11.10M	-$7.890M
YoY Change	224.77%	40.68%	89.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2660000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3360000	USD
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1435000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3683000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15292000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8667000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	713000	USD
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	919000	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	158000	USD
CY2014Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	188000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	188600000	USD
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	242222000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	138000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	4297000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	461000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4436000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1344000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1300000	USD
CY2013Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43000	USD
CY2014Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	70000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	259000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43000	USD
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17534000	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28831000	shares
CY2013Q4	us-gaap	Assets Assets	87976000	USD
CY2014Q3	us-gaap	Assets Assets	79492000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	28521000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	53455000	USD
CY2014Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6000	USD
CY2014Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	17000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	26000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47787000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24647000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51396000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32807000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18589000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-23140000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.47
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.50
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.35	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8540000	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14850000	shares
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20660000	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1975000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	425000	USD
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110100701	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121457118	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	121457118	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109425701	shares
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font><font style="font-family:inherit;font-size:10pt;"> — Financial instruments that potentially subject the company to significant concentrations of credit risk consist principally of cash and cash equivalents. The company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the company’s cash equivalents were invested in money market mutual funds. The company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The company has not experienced any losses on its deposits of cash and cash equivalents. The company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Cost Of Revenue CostOfRevenue	925000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	258000	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	258000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	247000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	8063000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	22660000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	46964000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	14828000	USD
CY2013Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0845
CY2013Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30M
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-63000	USD
CY2014Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	-5053000	USD
CY2014Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	88000	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	115000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	665000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1946000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1999000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7Y
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-62000	USD
	us-gaap	Gain Loss On Sale Of Securities Net GainLossOnSaleOfSecuritiesNet	0	USD
	us-gaap	Gain Loss On Sale Of Securities Net GainLossOnSaleOfSecuritiesNet	1392000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2014Q3	us-gaap	Goodwill Goodwill	5898000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1159000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	700000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-86000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2248000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1543000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2018000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-9287000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	64000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	363000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-68000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1000	USD
CY2014Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-297000	USD
CY2013Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-314000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-495000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-925000	USD
	us-gaap	Interest Paid InterestPaid	632000	USD
	us-gaap	Interest Paid InterestPaid	195000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	70000	USD
CY2014Q3	us-gaap	Interest Payable Current InterestPayableCurrent	63000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	116000	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	218000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	386000	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	450000	USD
CY2014Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	232000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	270000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	82090000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	48633000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79492000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87976000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	31586000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62447000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2149000	USD
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	4163000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7743000	USD
CY2014Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5097000	USD
CY2013Q2	us-gaap	Marketable Securities MarketableSecurities	5786000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	1392000	USD
CY2014Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2013Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	814000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1551000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20437000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	48262000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14405000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5419000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9236000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32126000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28650000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1795000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-6173000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28177000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28239000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6173000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8128000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28650000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21490000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13208000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6893000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40840000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28650000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28080000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11078000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6173000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	841000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	1636000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	330000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	643000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-2108000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax		USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	705000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-828000	USD
CY2014Q3	us-gaap	Other Income OtherIncome	597000	USD
CY2013Q3	us-gaap	Other Income OtherIncome	693000	USD
	us-gaap	Other Income OtherIncome	881000	USD
	us-gaap	Other Income OtherIncome	-59000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	693000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	597000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	881000	USD
CY2013Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1235000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9865000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	12190000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-6749000	USD
CY2014Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7035000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2315000	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2000000	USD
CY2013Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	554000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1789000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1399000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font><font style="font-family:inherit;font-size:10pt;"> — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share.</font></div></div>
CY2013Q3	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	13000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	13000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37520000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	263000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	69000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	35000000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5200000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1392000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4342000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	665000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	589000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	21000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	908000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7243000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22082000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3633000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13990000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
	us-gaap	Sales Discounts Services SalesDiscountsServices	0	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1620000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	6124000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1170000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1170000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7268000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8369000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23698000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4129000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4435000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1344000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.791
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7766
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7947
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0125
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0202
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0202
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5225000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	13429000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1792000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1235000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.78
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1551000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8994000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13159000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.73
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.34
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1088000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.31
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.42
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.57
CY2013Q3	us-gaap	Share Price SharePrice	2.00
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M15D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2012Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	17500000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3608000	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	37743000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	263000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6840000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4342000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	30859000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5886000	USD
CY2014Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30859000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5886000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2013Q3	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	172000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-59000	USD
CY2014Q3	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-597000	USD
CY2014Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	675000	shares
CY2014Q3	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Uses of Estimates in Preparation of Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div></div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84678612	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87319450	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	117767791	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	119038656	shares
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	13174000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	-7135000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-559000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	559000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	59000	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-13174000	USD
	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	5694000	shares
CY2013Q2	gale	Classof Warrantor Right Average Market Price Used For Exercise Price ClassofWarrantorRightAverageMarketPriceUsedForExercisePrice	P20D
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	300000	shares
CY2013Q2	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P7Y
CY2014Q3	gale	Closing Price Of Common Stock ClosingPriceOfCommonStock	4.84
CY2014Q3	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	642000	shares
CY2013Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6821000	USD
CY2014Q3	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	6880000	USD
CY2013Q4	gale	Contract Research Payable ContractResearchPayable	3109000	USD
CY2014Q3	gale	Contract Research Payable ContractResearchPayable	5601000	USD
CY2014Q3	gale	Credit Memos Acquisition Channel Inventory Current CreditMemosAcquisitionChannelInventoryCurrent	1384000	USD
CY2013Q4	gale	Credit Memos Acquisition Channel Inventory Current CreditMemosAcquisitionChannelInventoryCurrent	0	USD
CY2013Q2	gale	Debt Instrument Cash Facility Fee DebtInstrumentCashFacilityFee	0.01
CY2013Q2	gale	Debt Instrument Cash Final Payment DebtInstrumentCashFinalPayment	0.055
CY2013Q2	gale	Debt Instrument Term Interest Only DebtInstrumentTermInterestOnly	P12M
CY2013Q4	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-178875000	USD
CY2014Q3	gale	Deficit Accumulated During Developmental Stage DeficitAccumulatedDuringDevelopmentalStage	-207525000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	5389000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y8M1D
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	27026000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	8238000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity		USD
CY2014Q3	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	8765000	USD
CY2013Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	48965000	USD
CY2014Q3	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	8765000	USD
CY2013Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	48965000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	1.93
CY2014Q3	gale	Future Milestone Payment FutureMilestonePayment	3222000	USD
CY2013Q4	gale	Future Milestone Payment FutureMilestonePayment	0	USD
CY2013Q4	gale	Gale401rights GALE401rights	0	USD
CY2014Q3	gale	Gale401rights GALE401rights	9155000	USD
CY2014Q3	gale	Gross Revenueof Significant Order GrossRevenueofSignificantOrder	1500000	USD
CY2014Q3	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2013Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	1000000	USD
	gale	Issuance Of Common Stock In Settlement Of Contingent Purchase Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentPurchaseConsiderationMilestone	0	USD
CY2013Q3	gale	Loss On Warrant Exchange LossOnWarrantExchange	1614000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	7135000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-13174000	USD
CY2014Q3	gale	Loss On Warrant Exchange LossOnWarrantExchange	-6735000	USD
CY2014Q3	gale	Maximum Maturity Period To Consider All Highly Liquid Debt Instruments As Cash And Cash Equivalents MaximumMaturityPeriodToConsiderAllHighlyLiquidDebtInstrumentsAsCashAndCashEquivalents	P90D
CY2014Q3	gale	Mills Pharamaceuticals Milestone1 MillsPharamaceuticalsMilestone1	2000000	shares
CY2014Q3	gale	Mills Pharamaceuticals Milestone2 MillsPharamaceuticalsMilestone2	2000000	shares
CY2014Q3	gale	Mills Pharmaceuticals Maximum Shares Issuablefor Milestones MillsPharmaceuticalsMaximumSharesIssuableforMilestones	3000000	shares
CY2014Q3	gale	Mills Pharmaceuticals Pricepersharefloor MillsPharmaceuticalsPricepersharefloor	4.84
CY2014Q3	gale	Mills Pharmaceuticalspricepershareceiling MillsPharmaceuticalspricepershareceiling	6.84
CY2014Q3	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	48000	USD
CY2013Q3	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	51000	USD
	gale	Miscellaneous Other Income Expense MiscellaneousOtherIncomeExpense	0	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	820000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	10717000	USD
CY2014Q3	gale	Net Revenueof Significant Order NetRevenueofSignificantOrder	900000	USD
CY2014Q3	gale	Numberof Commerical Products NumberofCommericalProducts	1	products
CY2013Q2	gale	Numberof Days Averagedfor Exercise Price NumberofDaysAveragedforExercisePrice	P20D
CY2014Q3	gale	Numberof Dosing Strengths NumberofDosingStrengths	6	dosing_strength
CY2013Q3	gale	Numberof Shares Per Unit NumberofSharesPerUnit	1	shares
CY2014Q3	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	2484000	shares
CY2014Q3	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	1969000	USD
CY2013Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	2618000	USD
CY2013Q3	gale	Proceeds From Issuanceor Saleof Equity Net Underwriting Discounts Commissionsand Offering Expenses ProceedsFromIssuanceorSaleofEquityNetUnderwritingDiscountsCommissionsandOfferingExpenses	37500000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	27026000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	2070000	USD
CY2013Q4	gale	Sales And Distributions Rights SalesAndDistributionsRights	14979000	USD
CY2014Q3	gale	Sales And Distributions Rights SalesAndDistributionsRights	14714000	USD
CY2014Q3	gale	Sales And Distributions Rights Zuplenz SalesAndDistributionsRightsZuplenz	7663000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	562000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	182186	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	121457118	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE

Files In Submission

Name	View Source	Status
0001390478-14-000063-index-headers.html	Edgar Link	pending
0001390478-14-000063-index.html	Edgar Link	pending
0001390478-14-000063.txt	Edgar Link	pending
0001390478-14-000063-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gale-20140930.xml	Edgar Link	completed
gale-20140930.xsd	Edgar Link	pending
gale-20140930x10q.htm	Edgar Link	pending
gale-20140930xex101.htm	Edgar Link	pending
gale-20140930xex311.htm	Edgar Link	pending
gale-20140930xex312.htm	Edgar Link	pending
gale-20140930xex321.htm	Edgar Link	pending
gale-20140930_cal.xml	Edgar Link	unprocessable
gale-20140930_def.xml	Edgar Link	unprocessable
gale-20140930_lab.xml	Edgar Link	unprocessable
gale-20140930_pre.xml	Edgar Link	unprocessable
pipeline4a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2014 Q4 Form 10-Q Financial Statement

#000139047814000063 Filed on November 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2014 Q4 Form 10-Q Financial Statement

#000139047814000063 Filed on November 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls